top of page
Fintepla_US_logo_reverse.png
For loved ones who experience seizures associated with Dravet syndrome
2248337_0729.JPG

Dravet syndrome is a severe, early-onset epilepsy marked by frequent, prolonged seizures that resist conventional therapies. The condition puts a heavy burden on patients and families, revealing the urgent need for more effective treatments.

FINTEPLA is proven to reduce seizures by more than 75% in patients with Dravet syndrome, giving families back the moments that matter.  
“Having seizure-free moments allows Callie to live an 11-year-old’s life. By choosing FINTEPLA, her neurologist made a profound impact.”
– Darlene, caregiver and mother

The challenge

Despite FINTEPLA’s proven efficacy, many healthcare providers and caregivers remain unaware or uncertain of its potential. Concerns about cardiac side effects persist, along with doubts about whether it can deliver life-changing results. Our challenge was to reposition FINTEPLA as a foundational treatment for Dravet syndrome by showcasing its profound impact on seizure reduction and family well-being.

The solution

We developed the Sound of Profound campaign to bridge the gap between clinical efficacy and emotional impact.
This unexpected, empathetic initiative amplifies the voices and everyday moments of families who have experienced profound seizure reduction with FINTEPLA, celebrating the joy and normalcy that return with seizure-free moments.

CREATIVE APPROACH

We launched the campaign with 3 real-life video stories featuring patients with Dravet syndrome and their families, highlighting their unique journeys with FINTEPLA. The campaign expanded across multiple touchpoints, including:

 

  • Immersive videos showcasing profound seizure reduction

  • Digital and social media assets driving traffic to Fintepla.com

  • Engaging tradeshow booth and caregiver materials
    emphasizing efficacy

  • A family video project engaging the Dravet syndrome community


Each story focused on sound, using dynamic audio and visuals to deepen the connection with families’ real-life experiences.
By spotlighting the sounds that return when seizures are controlled, the campaign brought FINTEPLA’s efficacy to life in a deeply emotional way.

Creative vision

The Sound of Profound is a fully immersive, powerfully emotive print, digital, and social initiative that amplifies the real-life sounds of seizure-free moments for loved ones with Dravet syndrome and their families—both verbally and visually.

This is what seizure-free moments sound like.
“When we hear Emma say her name, it means so much.”
– Nicole, caregiver and mother

THE IMPACT

The campaign, with 6 patient video stories and counting, continues to make a lasting impression on caregivers by emotionally connecting with the Dravet community. It gives them a tangible way to experience the life-changing benefits of FINTEPLA, inspiring hope and action.

This is the sound of profound family moments.

The Sound of Profound Family Video Project invites more caregivers from the Dravet syndrome community to share their stories.

 

By participating, families can share videos of the everyday moments in their lives that are possible with fewer seizures, strengthening connections within the community and spreading awareness of FINTEPLA.

In June 2024, the Sound of Profound campaign was introduced at the Dravet Syndrome Foundation conference. This caregiver event provided a platform for sharing experiences and fostering a deeper sense of community among those affected by Dravet syndrome, demonstrating the campaign’s commitment to supporting families through every step of their journey.

Now there's a new rhythm of family LIFE.
“To see him smile and hear him laugh...it’s something you can’t describe.”
– Erika, caregiver and mother

RESULTS

54%

Microsite Engagement

59%

Display Ad Engagement

62%

Social Engagement

“At UCB, we’re honored to stand with these families, amplifying their voices, inspiring others with these special moments, and celebrating the everyday triumphs, big and small.”
– Ross Lu, Marketing Lead, Rare Syndromes, Epilepsy US
bottom of page